Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
Authors
de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G
Summary
Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.
Read the article